HeartSciences (HSCS) Amortization of Deferred Charges (2022 - 2026)
HeartSciences (HSCS) posted quarterly Amortization of Deferred Charges of $100833.0 for Q2 2026, down 8.29% year-on-year from $109950.0 in Q2 2025, and down 61.79% on a QoQ basis from $263880.0 in Q4 2025.
HeartSciences (HSCS) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
HeartSciences (HSCS) has reported Amortization of Deferred Charges for 5 consecutive years, with $100833.0 the latest figure, recorded in Q2 2026.
- Quarterly Amortization of Deferred Charges fell 8.29% year-over-year to $100833.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $584613.0 (up 104.5% YoY) and the FY2026 annual result came in at $495950.0, up 73.49% from the prior year.
- Amortization of Deferred Charges slipped to $100833.0 in Q2 2026 per HSCS's latest filing, from $263880.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for HSCS reached as high as $263880.0 in Q4 2025 and fell as low as $19498.0 in Q3 2023.
- A 5-year average of $84263.9 and a median of $63378.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges plunged 68.23% — and 2025, when it jumped 492.78%.
- Year by year, Amortization of Deferred Charges stood at $61381.0 in 2022, then advanced by 3.25% to $63378.0 in 2023, then slipped by 29.76% to $44516.0 in 2024, then soared by 492.78% to $263880.0 in 2025, then plunged by 61.79% to $100833.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $100833.0, $263880.0, and $109950.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn |
| 2 | Stryker | 128.80 Bn | 125.92 Bn | 3.81 Bn |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.37 Bn | 44.70 Bn | 1.29 Bn |
| 6 | Dexcom | 28.41 Bn | 27.30 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.33 Bn | 26.04 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.96 Bn | 26.38 Bn | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn |
| 10 | HeartSciences | 6.43 Mn | 4.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 100,833.00 |
| Apr 30, 2026 | 100,833.00 |
| Oct 31, 2025 | 263,880.00 |
| Oct 31, 2025 | 263,880.00 |
| Jul 31, 2025 | 109,950.00 |
| Jul 31, 2025 | 109,950.00 |
| Apr 30, 2025 | 109,950.00 |
| Apr 30, 2025 | 109,950.00 |
| Jan 31, 2025 | 109,950.00 |
| Jan 31, 2025 | 109,950.00 |
| Oct 31, 2024 | 44,516.00 |
| Oct 31, 2024 | 44,516.00 |
| Jul 31, 2024 | 21,454.00 |
| Jul 31, 2024 | 21,454.00 |
| Jan 31, 2024 | 20,719.00 |
| Jan 31, 2024 | 20,719.00 |
| Oct 31, 2023 | 63,378.00 |
| Oct 31, 2023 | 63,378.00 |
| Jul 31, 2023 | 19,498.00 |
| Jul 31, 2023 | 19,498.00 |